Literature DB >> 33860920

Author's Reply to Joerg Putzke et al. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".

Jingjing Qian1, Cong Bang Truong2, Kaniz Afroz Tanni2.   

Abstract

Entities:  

Year:  2021        PMID： 33860920     DOI： 10.1007/s40259-021-00474-x

Source DB:  PubMed          Journal:  BioDrugs        ISSN： 1173-8804            Impact factor:   5.807


× No keyword cloud information.
  2 in total

1.  Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs.

Authors:  A Bate; M Lindquist; R Orre; I R Edwards; R H B Meyboom
Journal:  Eur J Clin Pharmacol       Date:  2002-09-03       Impact factor: 2.953

2.  Author's Reply to Joerg Putzke et al. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".

Authors:  Jingjing Qian; Cong Bang Truong; Kaniz Afroz Tanni
Journal:  BioDrugs       Date:  2021-04-16       Impact factor: 5.807
  2 in total
  2 in total

1.  Author's Reply to Joerg Putzke et al. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".

Authors:  Jingjing Qian; Cong Bang Truong; Kaniz Afroz Tanni
Journal:  BioDrugs       Date:  2021-04-16       Impact factor: 5.807

2.  Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".

Authors:  Joerg Putzke; Scott Haughie; Kelly H Zou; Gopinath M Ranganna
Journal:  BioDrugs       Date:  2021-04-16       Impact factor: 5.807
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.